Field Medical Reports 94.2% Durability in Atrial Fibrillation Ablation Trial
Field Medical, Inc. has published 12-month follow-up data from its Field PULSE trial, showing a 94.2% vein durability rate for its pulsed field ablation system in treating atrial fibrillation.
Field Medical, Inc. announced that the Journal of the American College of Cardiology: Clinical Electrophysiology has published 12-month outcomes from its first-in-human Field PULSE trial. The study evaluated the FieldForce PFA System, a pulsed field ablation device, in patients with atrial fibrillation.
The trial reported a 94.2% per-vein durability rate, indicating the sustained effectiveness of the ablation procedure. The data specifically pertains to the system's optimized waveform, which the company refers to as "instantaneous ablation." This approach aims to provide a rapid and effective treatment for the heart condition.
The published results provide additional clinical evidence supporting the use of high-voltage focal pulsed field ablation. Atrial fibrillation is a common heart rhythm disorder that can lead to serious complications if left untreated. Effective ablation aims to restore a normal heart rhythm.
Field Medical stated that the data contributes to the broader understanding of pulsed field ablation techniques. Further analysis of the trial's results is ongoing, with the company anticipating continued development of its ablation workflow.